Item 5.02 Departure of Directors or Principal Officers; Election of Directors;


          Appointment of Principal Officers.

(b) Effective July 3, 2023, Dr. Rupert Vessey, Executive Vice President, Research and Early Development, has decided to leave Bristol-Myers Squibb Company (the "Company").

(e) In connection with his departure, Dr. Vessey will be entitled to (i) severance benefits in accordance with the Company's Senior Executive Severance Plan, and (ii) (A) pro-rated vesting of Market Share Units (MSUs) and Performance Share Units (PSUs) and (B) full vesting of his 2019 Restricted Stock Units Inducement Award, in each case, in accordance with the Company's equity award agreements under the Company's 2012 and 2021 Stock Award and Incentive Plans. In addition, Dr. Vessey will receive a pro-rated annual incentive payout for 2023 in the amount of $550,855.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits

The following exhibit is included as part of this Current Report on Form 8-K:



Exhibit
  No.     Description
  104     The cover page from this Current Report on Form 8-K formatted in Inline
          XBRL (included as Exhibit 101).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses